Newron Pharmaceuticals S.p.A. Profit Margin

The latest profit margin for NP5.DE is -5.91% as of June 2026. That compares with -220.23% in the prior-year period — up 97.3% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Newron Pharmaceuticals S.p.A.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, NP5.DE's profit margin moved from -220.23% to -5.91% — a 97.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Newron Pharmaceuticals S.p.A.'s valuation or profitability profile.

Against Healthcare companies, NP5.DE currently prints -5.91% for profit margin, while the sector average sits near 10.58%. That is roughly 155.9% below the sector mean. Large gaps often invite a closer look at Newron Pharmaceuticals S.p.A.'s growth, margins, and balance sheet.

Profit Margin shows how effectively Newron Pharmaceuticals S.p.A. converts resources into returns. At -5.91%, NP5.DE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -220.23% in the prior-year period — up 97.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NP5.DE's profit margin (-5.91%), review year-over-year change from -220.23%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.